Weekly Digest - November 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - November 2024
07 Nov 2024: AstraZeneca to build Antibody Drug Conjugate (ADC) manufacturing facility in Singapore
- AstraZeneca held a groundbreaking ceremony on November 7 for its new Antibody Drug Conjugate (ADC) Manufacturing Facility in Singapore, marking a significant expansion in ADC capacity with a $1.5 billion investment
- The facility will span 58 acres (over 2.5 million square feet) and is expected to be operational by 2029, making it AstraZeneca’s largest initial investment to date
- The greenfield facility will be AstraZeneca’s first end-to-end ADC production site, designed to achieve LEED Platinum certification and operate on 100% renewable energy, targeting net-zero carbon emissions from day one
- The facility aligns with AstraZeneca’s Oncology R&D strategy, which includes a diverse portfolio of ADCs, six of which are in clinical trials, and plans for multispecific ADCs that target multiple proteins on tumor cells for improved efficacy and reduced side effects
